論文

国際誌
2022年9月

Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model

Journal of Infection and Chemotherapy
  • Naomi Matsumoto
  • ,
  • Hideharu Hagiya
  • ,
  • Masanori Nakayama
  • ,
  • Masanori Furukawa
  • ,
  • Toshiharu Mitsuhashi
  • ,
  • Soshi Takao
  • ,
  • Fumio Otsuka
  • ,
  • Takashi Yorifuji

29
1
開始ページ
39
終了ページ
42
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.jiac.2022.09.012
出版者・発行元
Elsevier BV

BACKGROUND: To mitigate the COVID-19 pandemic, many countries have recommended the use of booster vaccinations. The relationship between the degree of adverse vaccine reactions and elevated antibody titers is of interest; however, no studies have investigated the temporal changes in antibody titers based on repeated measurements after a third dose of the BNT162b2 vaccine. METHODS: This prospective longitudinal cohort study was conducted with 62 healthcare workers who received a third dose of the BNT162b2 at Okayama University Hospital, Japan. Venous blood draw and fingertip whole blood test sample collection were conducted at the early (3-13 days) and 1-month time points; only FWT sample collection was conducted at the 2-month time point. Information on adverse reactions within 1 week after vaccination was also obtained. The association between fever of 37.5 °C or higher and antibody titers after the third dose of BNT162b2 was examined using a mixed-effects model and Poisson regression with robust variance. RESULTS: A trend toward higher antibody titers in the early period after vaccination was observed in the febrile individuals, but the differences were not significant at 1 and 2 months post-vaccination (the partial regression coefficient for fever was 8094.3 [-1910.2, 18,098.8] at 1 month after vaccination, and 1764.1 [-4133.9, 7662.1] at 2 months after vaccination in the adjusted models). CONCLUSION: The findings suggest that the presence of fever after the third vaccine does not predict a sustained elevation in serum antibody titers.

リンク情報
DOI
https://doi.org/10.1016/j.jiac.2022.09.012
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/36168999
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484104
ID情報
  • DOI : 10.1016/j.jiac.2022.09.012
  • ISSN : 1341-321X
  • PubMed ID : 36168999
  • PubMed Central 記事ID : PMC9484104

エクスポート
BibTeX RIS